stronger than Charles believe River ever is that been. We morning. company today a it's Good
which enhance in enable with growing to invested tremendous and to new demand solutions and and responsiveness model, work outsourcing and with improvement strengthen to client open devise a market, accommodate increase a our which and our to have ways productivity to and them to in which efficiency to scalable speed people scientific are them maintain our to continuous effort to to clients. relationships create our leadership, clients employees of operating improve and build culture We working capacity to add time over
We drug maintained our focus forward XX which portfolio was and April step new on capabilities our require with was support to another strategically of provide acquisition expanding safely drugs. discover, the strategy. and research manufacturing on clients develop early-stage they solutions, our to The critical manufacture completed in CiTox
to industry-leading our even an of we so, long-term pace to our to in continue portfolio from with move our markets. By and will stronger to value in and become efforts research clients' innovation partner. strategic invest and and we fulfill ourselves our will provide discovery the fast enhance drug We the goals further competition to the doing enhance differentiate development
companies positioned companies outsource, their have exceptionally to initiatives institutions when drugs. biopharma make to to working are for global investing to well pipelines, compete now pharma are discover us decisions academic funding in are continuing new and These companies aggressively with new business biotech
and the of of a as biotech strong funding. Our results industry execution including as strategy effectiveness second demonstrate the its well we the quarter on made continuation that have fundamentals, our progress
share quarter prior organic and X.X%, second As X% double-digit outlook. within range low anticipated, our full to growth revenue of exceeded was our per prior growth year earnings
XXXX to May. exceed meet expect guidance the in financial we or we result, provided a As that
The our across funds second in million operating continued perspective, of strength as margin funding in and drug XXXX, research. the second growth business continued environment -- the points basis decrease the I was performance. revenue areas From year-over-year. remained quarter revenue biotech increase will year. robust X.X last clients of segments. quarter with was revenue reported now of drive XX.X%, of each provide growth highlights over a $XXX.X XX.X% reported invested a our of client Organic We of a XX to new X.X%
On drivers the since headwinds have structure XX margin Insourcing expansion Manufacturing last The primary were year, margin the of basis, operating RMS that Solutions and we the the the decline. the segments points. the the segment compensation reduced contract basis Biologics adjustment, capacity large mentioned and by
per revenue earnings to a outlook rate operating positioned our $X.XX, to X.X% outlook. in X.X%, We of year-over-year. XX.X% X.X% our to of the an per growth of well With share achieve the XX% last range earnings increased to guidance Earnings growth quarter represents year. per a non-GAAP contributed and to the $X.XX $X.XX reflecting tax increase the our share of This are we revenue $X.XX increase, of Strong organic half tax to rate year-over-year while in organic by first second the XX% $X.XX growth at growth expectation versus our for a lower of in higher were XXXX. prior quarter, income from drove revenue lower-than-anticipated second outperformance year. updated share
second well, I'd an with an performance, was increase like with X.X% you segment. on the segment on details Assessment organic over Both basis DSA Safety of to second Revenue quarter provide quarter from in the quarter, the the beginning very Discovery XXXX. million, $XXX.X Assessment biotech had clients Services benefiting from and and demand pricing. continued outpacing second robust businesses Safety Services Safety moderately the to increased Assessment with Discovery growth quarter. strong another perform revenue
bookings Our growth our organic continued proposal outlook utilized, Assessment high segment and for remained well to for global single-digit the activity year. the reinforce DSA in Safety and capacity
well biotech the midsize and our clients clients and April, their present extensive always expedite their our are our an which biopharma scientific value with global we clients, global our have a acquisition on to the whether dedicated improving reliance expansion, in are scale resources. operating or more positioned to clients of our of efforts. support capabilities which research even our Citoxlab As to relied require in working CROs compelling And result portfolio and they and on focus increasing small provide external exceptionally relationships, order on efficiency drug customized developing flexible enhancing capabilities,
and seamless have benefits they client to experience might sites work encourage clients Our shared increasingly services. and growth lead across to we client start a infrastructure demonstrates sites. capacity clients resources continue that believe and our responsiveness and across we offers To than studies. be that single we speed utilization. the enhance manage optimized we important our with broader all clients, will It that with to capabilities has to it and a of can recognize for become significant times our and efficiency our This our which larger clients value demand work much they multiple operating the through site also reduces at access provide, ensure
a already scheduling notable This, in and of the turn, times. Assessment to beginning improves are the mobility, prior used rates our client over able in requirements our benefits to We sites encourage because the of by to tighter Safety quarter clients start proposal we're year. efforts increase win see our in second our number clients' the with meet
scientific further from The was Citoxlab days. accomplished to Citoxlab's both the those and was that network pleased Citoxlab's to remain its stronger at sites company to enhancing initial share the clients, River had been feedback the is of to XX for I'm our and and and and have paying colleagues early forge was future as among are to work for we teams operational Chief smoothly, their of leading optimistic to the and teams career in progressing pathology And opportunities other case key to opportunities both major and integration early-stage and groups very teams position has role our River set have of MPI, approach practices for as including as to of to achieve and positive. relationships. our with sites. the and the previously X drive collaboratively the engaged leveraging CRO. in about million integration first begin met talented synergies, say over We staff collaborative goals $XX the more are we positive This is the outsourced. that motivated WIL Charles seamless global already the operational work recognized CiTox best Charles have $X across combined synergies laboratory growth play and as million Citoxlab next years we some in continue dividend confident conduct ability a sciences
had utilization of project a client the second led an well larger by integrated proposals new discovery in in rate wins strong the Discovery their services our as of are for discovery year. in for early the us programs. or win solid excellent business quarter, a quarter, demand our The discovery our strong for single San as programs drug to for on as services Francisco. for strengthen These continues South clients discovery was our with building integrated in highest-ever second site early projects very discovery pipeline early leading projects. Client partner these to for half interest Demand
We our transporter The continued in drug-drug additional portfolio solutions and capabilities to drug footprint. provides expand to discovery enhance efforts. of research addition client's Citoxlab's interaction and Discovery drug our discovery
capabilities, and are this Coast site, beginning from a DMPK our at discovery biotech to of bioanalytical at San placing increasingly wider clients which West addition, base. CNS of opened work South In fast-growing to discovery expanded this range services, Francisco year. the offers client It
stickiness stages research enhance to at add as continued will portfolio, drug pipeline. their programs as also solution or we client comprehensive opportunities to believe We evaluate innovative our progress capabilities a discovery the earliest through retention to creating the of
Our recent prime with alliance of this. Distributed a is example Bio
to are interest. provider We comprehensive -- to for portfolio Discovery continue combined as single to discovery discovery reinforce range build premier of considerable source generating capabilities large the our our position molecule services. bind client to Our intend a
year-over-year Notwithstanding headwind small anticipated. operating decline quarter. This the by structure. but a of higher partially year-over-year points income offset compensation in pricing tax and caused improved basis related basis quarter, this margin year's was sequential by declined principally our in R&D second credits as costs on significantly associated to the the to DSA benefit staff with we XX acquisition. a operating capacity the acquisition adjustment the Citoxlab including XX.X% last from and margin The investments, was Citoxlab second created benefit, The to higher
half the operating help on of adjustment anniversary first expect compensation the July will in client into the continue We the to support structure margin X staff second primarily slower demand. half sequentially improve DSA after of additions of the hiring year, of and year by the acceleration driven to strong an the the
an the first was to Services demand The primary continued increase for of models for revenue over an RMS be growth revenue $XXX.X research of Model basis XXXX. drivers of and X.X% RMS million, Research on quarter organic in China. strong
perspective, increase. contributed with basis to points commenced services Solutions which revenue a XXX NIAID, From last approximately September, contract Insourcing the
their for continued research vivarium management contract, clients the took benefits Solutions NIAID well of very flexible Insourcing from the as from the Aside business solutions related advantage and to needs. our perform
Last were in turnkey Development biohub, open small Boston/Cambridge San quarter, initiative, month discussed or Charles CRADL clients the of the expansion early Accelerator research success River and our is pleased the Francisco to XXXX. provide planned biohub. large capacity We both CRADL we initiative our to with expected and announce the South in of which to earlier this Labs, to pharmaceutical
to expertise site. staff and Charles our continue a vivarium We a support of a River option at arrangements traditional variety from a working flexible providing at where site, we vivarium through to to insourcing provide CRADL manage client clients space of
to help and complex increasingly expertise therapies. research with them because business colonies becomes of also faster us and clients' other effectively. oncology, cost create shift a critical we and use proprietary more more have technologies from and our to and come models to an which genetically maintain as disease, derive GEMS role cell Clients gene drug modified the to a model to rare Our benefit continued CRISPR play
of businesses, us, and all XX% to opportunity Outside is we in to achieve growth market growth continue a to is by production model new model business goal, research over increasing biopharma, be share longer from services for large largely single-digit Revenue achieve the several a factors increases. of our continue of our which performing continues goal demand to our China. to generate segment of these that from very throughout present for Research have regions in continuation Model been expect years: Combining low declining expectations growth a and and RMS to with consistent intend in China, To this capacity The well. China. for trends market continued continued term. China expect the we China research be China, to for in price our driven growth significant the add we biotechs demand
year. lower NIAID be decreased contract, The NIAID points outside demand RMS X to the adjustment, for new The the of contract enhance was to driving To XXX of enterprise, second the mature structure operating a the compensation margin The margin. the offset lower-margin and structure by from of volume adjustment RMS we half driven pressure during markets, research factors: will ways China. -- reduction at to to and anniversaried from to compensation more by efficiency, sustaining digital decline XX.X%. help cost basis look the headwinds goal operating models with RMS towards continue in the operating
both Manufacturing an million, organic X.X% the was by quarter year. $XXX increase Biologics on Solutions Microbial businesses. Support segment for the of and Solutions the strong Revenue basis a over was last increase demand across second The Testing driven
Microbial growth Solutions low-double with had the in another strong digits. quarter
Celsis testing by demonstrated quality Endosafe solutions. robust provider line testing Accugenix services bioburden only offer products. a and continued test -- quarter. this beginning the control expedite sterility with reagents, is our core launched used to had across testing as their advantage gain Our methods demand microbial can release identification clients, for solution replace our the particularly systems pharmaceutical comprehensive and new project strong was a rapid resonate our cartridges, to adoption Celsis who a product which Celsis a to of and manual year, of Sales already rapid which earlier We client
We future also continued operational enhancements. and growth, to through including expansion invest to support geographic
Shanghai investing China operating a stronger in are in enhance Solutions We in the further Microbial improvements also are to a growing efficiency. create to market process opening site presence and
of still in quarter, Revenue very the the dipped quarter good molecule development the had the in in continue by to XX% new growth year. the and number growth biologics and innovative overall, the Revenue business large driven we a in cure as low pipeline below needs. second to was in for business but growth expect Biologics double medical the slightly the digits level robust unmet by drug the drugs solutions demonstrated the
globally. enhance this is Pennsylvania of the to our services, continues we accommodate are To facility, end be expansion, year. new and capacity demand completed these the transition and as the critical is a well, by premier which adding to global position our provider of the In progress largest expected
to to As however, of services This the we facilities segment's the a as we we in transfer mentioned the margin the second X are order to duplicate XX seamless site our that clients. is past, operating have transition ensure new for the is in creating basis the headwind point half transition, these expected costs during in the in year. during the resulting moderate operating to quarter; costs are second
year-over-year. operating quarter decrease businesses the was I mentioned. basis growth support and XX.X%, both in second segment Manufacturing margin Solutions primarily The a XXX related previously decline that was costs to Microbial The higher Biologics to investments point from
in margin and business had quarter the level of The headwinds regularly we than second dissipate. mid-XX% linear we quarter segment's the fourth margin anticipated. But slightly these our said, was as many have is not we lower expect as approach operating the Manufacturing to
the recognize as become scientific go-to an expanding the commitment our early-stage number who partner and for global our of enhance CRO, to deep continue them. scale to position clients we leading have expertise, As we
become of the productive drug increasingly choose in-house critical expands with and integral utilize or capabilities experienced research, studies River or clients about their Working their where to partner more our to go have internal expertise because they pipelines. projects augment and We collaboratively interpret as results decisions most the with and an to or scientific the us and bandwidth the early-stage solution part they to have infrastructure no Charles efficient design CRO. no-go clients' make
across Therefore, increases our importance rely portfolio. as increasingly expertise scientific expand they array solutions. our wider a Our of on clients we our to broad
our for our execution responsiveness portfolio the superb flexibility and our and that with our scientific expertise, the growth. relationships believe continued basis and long-lasting and future of We are expansion clients our
view are the as expanding intense focus we provide to on the our for We clients. value maintaining initiatives we critical that
remain strategic technologies generating in support edge fuels research acquisitions molecule pipelines to in whether unique in to market. through leading to continues emerging cutting-edge continuing The are our which solutions arrangements discovery in enhance drug scientific We the and growth. biotech as the the to our of our therapeutic our such the that investments the such be industry, is significant with our of by to as of turn, add portfolio and opportunities to on manufacturing to research further this expertise innovation drug on Distributed on with assess or in of drugs investing Bio. capabilities, We partnership the it capitalize large-molecule fuel innovation pipeline intend early-stage funding new scientific trends, as proliferation area internal large better well broaden as
data, While our seamlessly invest also and resources we and continue acquisitions necessary and their are more from and the achieve of in needs, our be to value. By will in strategy, ourselves growth, and with us able future our scientific shareholder technology to aim partner work with current broader which support clients staff spectrum we further our so, component efficiently differentiate their will to in goals scientific a support clients and of the expertise a to to competition. vital growth growth to protect our to doing enhance long-term help
In work their our and like employees conclusion, shareholders their thank exceptional commitment. for support and to and clients for I'd our
will results you our details Smith and XXXX additional on second give David guidance. Now quarter
